and absolute urinary excretion of UA (UE UA ) and sodium (UE Na ), and urine pH were determined.
| INTRODUCTION
In humans, uric acid (UA) is the final breakdown product of purine nucleotides, which originate from exogenous dietary sources, and from endogenous de novo synthesis and tissue catabolism.
1,2 UA formation from purines occurs mainly in the liver, with a prominent role for xanthine oxidase, the rate-limiting enzyme in UA biosynthesis. 3, 4 Normally, >70% of UA is excreted into the urine, with a fractional excretion of 5% to 10%, while the remainder is excreted through the intestines and perspiration. 3, 5, 6 Hyperuricaemia is usually defined as a plasma UA level > 6.8 mg/dL (405 μmol/L, corresponding with its solubility point) 6 and can be caused by reduced excretion by the kidney, accounting for 90% of cases of hyperuricaemia, or by UA overproduction in the liver. 3 Hyperuricaemia can result in deposition of UA crystals, leading to gout and nephrolithiasis. Moreover, evidence suggests that increased plasma UA levels, although in the high normal range, 4, 7 are an independent risk factor for impaired fasting glucose, diabetes mellitus, hypertension, heart failure, coronary heart disease and chronic kidney disease. 8 Accordingly, the indication for plasma UA-lowering therapy, with either xanthine-oxidase inhibitors or uricosuric agents, may be broader than that for gout or UA nephrolithiasis.
Interestingly, in studies in diverse populations including type 2 diabetes mellitus (T2DM) patients, 4,9-11 plasma UA-lowering therapy improved surrogate cardio-renal end points, although dedicated large-sized trials, such as the ongoing ALL-HEART study (ISRCTN32017426), are needed to firmly establish causation between UA lowering and long-term clinical outcomes. patients indicate the beneficial effect of 2 of these drug classes on cardiovascular and renal events and mortality: (1) glucagon-like peptide-1 (GLP-1) receptor agonists (RA) (ie, liraglutide 12, 13 and semaglutide, 14 but not exenatide once-weekly, which tended [P = .06] to reduce cardiovascular risk 15 ) and (2) sodium-glucose co-transporter-2 (SGLT2) inhibitors (ie, empagliflozin 16, 17 and canagliflozin 18 ). Delineation of the underlying cardio-renal protective mechanisms may have immediate relevance for prevention and treatment of diabetes-related complications, but many uncertainties remain. For SGLT2 inhibitors, some have suggested that benefits are explained, in part, by their ability to reduce serum UA levels, probably through increased urinary UA excretion. 19 The effects of GLP-1RAs on plasma UA levels and urinary excretion of UA (UE UA ) in humans are hitherto unknown. In rats with streptozotocin-induced (type 1) diabetes, daily GLP-1-peptide injections for 10 weeks reduced serum UA concentrations by 58%, compared to untreated diabetic rats. 20 As GLP-1RA administration inhibits Na + /H + -exchanger type-3 (NHE3) activity in the proximal tubule, causing natriuresis and alkalization of the urine, [21] [22] [23] [24] we hypothesize that this antihyperglycaemic drug class may reduce plasma UA levels by increasing urinary UA excretion in humans, those with and those without T2DM. [25] [26] [27] To explore the effects of currently available GLP-1RAs, with clinically relevant differences in their pharmacokinetic profile (see below), on plasma UA and UE UA , we performed a post-hoc analysis of 4 clinical trials that assessed the effects of these drugs on kidney physiology. 21, 22, 24, 28 A detailed overview of trial designs and testing procedures is shown in Figure 1 . Study-A was an acute, non-blinded, placebocontrolled trial, examining the effect of placebo (isotonic saline) and subsequent exenatide infusion at therapeutic concentrations in healthy overweight men. 21 Study-B was an acute, randomized, double-blind, placebo-controlled, parallel-group trial, examining the effect of exenatide infusion in T2DM patients. 24 Patients from Study-B were subsequently enrolled in Study-C, which was a 12- 
| Study protocols
Two days prior to testing procedures, participants were instructed to adhere to a controlled intake of protein (1. and infusion of kidney tracer substances (dominant side). Blood and urine were obtained for outcome variables as previously described in detail. 21, 23, 24, 28 Subsequently, kidney tests commenced as previously described in detail. 21, 23, 24, 28 In all studies, a bolus of inulin was administered over 10 minutes, which was followed by a continuous infusion over 90 minutes; this served as an equilibration period.
In Study-A, subjects subsequently underwent 2 consecutive urine collection periods of 45 minutes during placebo infusion, which were repeated after 60 minutes of infusion with exenatide ( Figure 1 ). 21 In
Study-B, participants subsequently underwent 2 urine collection periods of 45 minutes at baseline, which were repeated after 60 minutes of infusion with exenatide or placebo ( Figure 1 ). 24 In
Study-C, the baseline measurements of Study-B were repeated after 12 weeks of treatment with liraglutide or placebo ( Figure 1 ). 28 In In all studies, diuresis was prompted by oral intake of 10 mL/kg (maximum 1000 mL) tap water during the inulin equilibration period, followed by an intake of 200 mL/h for the remainder of the testing day. Before and after each urine collection period, blood samples were taken to obtain outcome variables as described previously in detail. 21, 23, 24, 28 UA-excretion was measured over the second of 2 consecutive urine collection periods in Study-A-Study-C, and over both of the 2 urine collection periods in Study-D.
| Biochemical analyses
UA was measured as urate, using an enzymatic colorimetric test (Cobas-C501, Roche Diagnostics, Indianapolis, Indiana) and urine pH was buffered to >8.0 with NaOH. Inulin was analysed as described previously. 24 Routine blood determinations (HbA1c, glucose, sodium, osmolality and creatinine) were performed at baseline and after prolonged therapy, using conventional assay methods, by the Department of Clinical Chemistry at the VUMC. Venous blood glucose was measured throughout the kidney tests using an YSI-2300 STAT glucose analyser (YSI Life Sciences, Yellow Springs, Ohio). Insulin was determined using an immunometric assay (ADVIA Centaur-XP Immunoassay System, Siemens Healthcare, Erlangen, Germany). Crossreactivity of the assay with insulin glulisine (low) and insulin glargine (high) has been described. 22 Urine pH was measured by a hand-held VARIO 2V00 pH meter and SenTix-V electrode (WissenschaftlichTechnische Werkstätten GmbH, Weilheim, Germany).
| Outcomes
In all studies, plasma UA, fractional and absolute UE of UA (UE UA ) and sodium (UE Na ), GFR, urine pH, urine osmolality, insulin (serum or plasma) and glucose (blood or plasma) were measured. Urinary glucose was determined in Study-B-Study-D. In Study-C, fractional UE UA was additionally assessed at weeks 0, 2 and 12.
| Calculations
Fractional UE UA and UE Na were calculated by using inulin as a reference substance, unless stated otherwise. Absolute electrolyte excretions were calculated by multiplying urinary electrolyte concentrations by urine flow. GFR was calculated from inulin clearances. GFR and absolute electrolyte excretion were corrected for body surface area using the Mosteller formula. 3 | RESULTS
| Study-A
The study population comprised 9 subjects (Table 1) . 21 , P = .02) ( Figure 2 ). As previously reported, exenatide increased GFR, fractional UE Na , absolute UE Na , urine pH (from 6.53 (6.03-6.90) to 7.04 (6.89-7.34), P = .005) and osmolality (Table S1 in Appendix S1). 21 Exenatide reduced plasma glucose, without affecting plasma insulin concentrations (Table S1 in Appendix S1). 21 Changes in fractional UE UA and absolute UE UA correlated with changes in urine pH (r: 0.90, P = .001 and r: 0.82, P = .007, respectively) ( Figure 3A ,B), but not with changes in plasma UA (r: −0.20, P = .6 and r: −0.35, P = .4), in glucose (r: 0.58, P = .1 and r: 0.27, P = .5) or in insulin (r: 0.17, P = .7 and r: 0.26, P = .5). Changes in fractional UE UA correlated with changes in fractional UE Na (r: 0.75, P = .019) ( Figure 3C ). Changes in fractional UE UA , absolute UE UA and plasma UA did not correlate with baseline plasma UA (all P > .3).
| Study-B
The study population comprised 52 patients (Table 1) . 24 Mean AE SD baseline UA was 5.50 AE 1.04 mg/dL (9 patients were hyperuricaemic) and did not change during immediate exenatide-infusion compared to placebo (−0.01 AE 0.02 mg/dL, P = .8). While UA levels were not affected, exenatide-infusion increased fractional UE UA (+0.76 AE 0.38%, P = .049) and absolute UE UA (+0.75 AE 0.27 mg/min/1.73 m 2 , P = .007), compared to placebo ( Figure 2 ). As previously reported, exenatide increased fractional UE Na , absolute UE Na , urine pH (+0.72 AE 0.11, P < .001) and urinary osmolality (Table S2 in Appendix S1). 24 Urinary glucose at baseline was <0.11 mmol/L in all but one patient (0.97 mmol/L) and was not affected by exenatide. 24 Exenatide infusion reduced blood glucose during kidney tests, and increased serum insulin concentrations compared to placebo (Table S2 in Appendix S1). There were no changes in plasma renin concentrations (PRC). 24 In regression analyses, exenatide-induced alterations in fractional In the exenatide arm, changes in fractional UE UA , absolute UE UA and plasma UA did not correlate with baseline UA levels (all P > .6).
| Study-C
The study population comprised 36 patients (Table 1) . 28 Mean AE SD baseline UA was 5.39 AE 1.07 mg/dL (6 patients were (44) 15 ( hyperuricaemic). After a 12-week treatment with liraglutide, no alterations in UA (P = .8) (Figure 4A ) or in UE UA (Figures 2 and 4B) were observed compared to placebo. As previously reported, GFR, UE Na , PRC, urine pH, urine osmolality and urinary glucose excretion were not affected after 12 weeks of treatment (Table S3 in   Appendix S1) . 28 Yet, compared to placebo, liraglutide reduced HbA1c by 1.3 AE 0.2% (P = .001), plasma glucose by 1.3 AE 0.3 mmol/L (P < .001) and body weight by 1.9 AE 0.7 kg (P = .009). 28 There were no changes in PRC. 28 At Week 2, no changes in UA (P = .8), creatinine-based fractional UE UA (−1.55 AE 0.88%, P = .09) or fractional UE Na were observed in the liraglutide arm compared to the placebo arm ( Figure 4A,B) . 28 In the liraglutide arm, but not in the placebo arm, changes from baseline to Week 12 in plasma UA correlated with baseline plasma UA (r: -0.52, P = .022) ( Figure 5 ), while fractional UE UA or absolute UE UA did not correlate with baseline plasma UA (both P > .5) or with changes in plasma UA (both P > .06). No correlations were observed in the liraglutide arm or the placebo arm between changes from baseline to Week 2 in creatinine-based fractional UE UA and baseline plasma UA (P > .6).
| Study-D
The study population comprised 35 patients (Table 1) . At baseline, mean AE SD fasting UA was 5.68 AE 1.19 mg/dL (7 patients were hyperuricaemic), which decreased after the meal by 0.09 AE 0.04 mg/ dL (P = .03). Prior to randomization, creatinine-based fractional UE UA tended to increase slightly after the meal by 0.02 AE 0.01% (P = .051).
After 8 weeks of treatment, fasting and postprandial UA did not differ between or within treatment arms (all P > .1). Within groups, lixisenatide treatment did not affect postprandial fractional UE UA (P = .6) or absolute UE UA (P = .9), while insulin glulisine reduced fractional UE UA (−1.52 AE 0.64; P = .03) and tended to reduce absolute UE UA (−0.65 mg/min/1.73 m 2 ; P = .052). This resulted in significant between-group differences ( Figure 2 ). As previously reported, urine pH and fractional UE Na increased with lixisenatide compared to insulin glulisine in the postprandial state, while GFR was not affected (Table S4 in Appendix S1). 23 Postprandial urinary glucose did not differ between (P = .2) or within groups (both P > .6). Compared to insulin glulisine, lixisenatide did not change HbA1c (P = .9), but decreased blood glucose during kidney tests by 1.8 AE 0.5 mmol/L (P = .002).
Within groups, insulin concentrations decreased with lixisenatide (Table S4 in Appendix S1). 23 Body weight decreased by 1.4 AE 0.6 kg with lixisenatide compared to insulin glulisine (P = .03). 23 No withinor between-group differences in postprandial PRC or angiotensin II were observed. 23 In the lixisenatide and insulin glulisine arms, fulfilled the criteria of hyperuricaemia).
Recent landmark cardiovascular safety trials indicate that GLP-1RAs
provide cardiovascular and renal benefit compared to placebo (ie, standard of care) in at-risk T2DM patients after prolonged therapy. [13] [14] [15] 32 However, underlying cardio-renal protective mechanisms remain incompletely understood. Hyperuricaemia is frequently observed in patients with pre-or recent-onset T2DM, 33 and increased levels of UA are thought to mediate, in part, cardiovascular and renal risk in T2DM. 4, 8 As GLP-1-peptide administration for 10 weeks in diabetic rats reduces UA levels, 20 and GLP-1RAs exhibit clinically relevant tubular effects in humans, [21] [22] [23] [24] we hypothesized that GLP-1RA administration lowers plasma UA by increasing kidney UA clearance. [25] [26] [27] Although intravenous exenatide administration rapidly increased UE UA in overweight healthy subjects (Study-A) and T2DM patients (Study-B), no reduction in UA-levels was observed. This could be explained by the short duration of the studies, although we cannot exclude that exenatide concurrently increased UA production. Furthermore, upon prolonged treatment with either a short-acting or long-acting GLP-1RA, we did not observe effects on UA clearance or UA levels. As such, our results indicate that it is unlikely that UA is a relevant clinical mediator of the recently described cardio-renal benefits of GLP-1RAs in T2DM patients.
Although the tubular handling of UA in humans is incompletely understood, we propose several mechanisms by which exenatide infusion could have immediately increased UE UA in our studied populations, based on correlation and regression analyses. The effect seems to be driven, to large extent, by a concurrent increase in urine pH and, in part, by an increase in UE Na . by lowering angiotensin-II. 2 However, as we and others 40, 41 did not observe changes in PRC or angiotensin-II, there seems to be no important role for the circulating RAAS, although a contribution of the intrarenal renin-angiotensin system cannot be excluded.
In order to explore the sustainability of the immediate GLP-1RA-induced effect on UE UE , and to determine whether this translates into lowering of plasma UA upon long-term treatment, we analysed the data to decrease the gastric emptying rate and to inhibit areas in the central nervous system involved in hedonic feeding are not sustained during prolonged treatment. 29, 30 In line with these observations, we recently suggested that tachyphylaxis and/or induction of compensatory mechanisms at the tubular level explains that only short-acting GLP-1RAs harbour sustained natriuretic and urine-alkalizing actions during prolonged treatment. 23, 28 We hypothesized that such divergent actions could also In comparison, the initial stimulating effects of an SGLT2 inhibitor on UE UA also seem to wane upon prolonged intervention, as suggested by a mechanistic study in healthy subjects and by in vitro transport experiments. 43 However, in contrast to current GLP-1RA data, chronic SGLT2 inhibitor therapy does have a sustained suppressive effect on plasma-UA, 36 suggesting that these drugs establish a new steady state in UA metabolism and clearance.
Notably, our correlative analyses suggest that prolonged GLP-1RA treatment may lower plasma UA in T2DM patients with higher baseline plasma UA levels. However, as a similar relation is observed in patients treated with insulin glulisine, a glucose-dependent mechanism is suggested. 35 Accordingly, individual responses in renal UA handling were not associated with changes in plasma UA, although the isolated correlation of changes in absolute UE UA with plasma UA in patients treated with lixisenatide merits further research.
The described studies are not without limitations. First, intestinal UA excretion and UA formation were not assessed. Such measurements are technically challenging, and intestinal excretion was not expected to be affected substantially. 3 UA formation could theoretically be influenced by treatment through alterations in circulating fructose levels. 35 We did not assess fructose levels in these trials, but emphasize that this would be confounded by glucose lowering. Second, we did not measure UA crystallization as the increment in urine pH dramatically improves UA solubility, especially with pH > 6.0 to 6.5, 44 rendering the likelihood of precipitation negligible. It is tempting to speculate that this would potentially also prevent UA-mediated tubulopathy. 35 However, we did not observe any effects on glomerular and tubular injury markers (albumin-creatinine ratio, KIM-1 or NGAL)
as previously reported in T2DM patients without overt nephropathy. 23, 24, 28 Third, since the intervention conditions in Study-A were performed sequentially, we cannot exclude time-dependent effects.
This may explain the somewhat unexpected slight increase in plasma UA after immediate exenatide infusion in healthy subjects. Fourth, our T2DM population had a prolonged history of diabetes and we did not specifically include patients with (symptomatic or asymptomatic)
hyperuricaemia, which does not allow generalization of the current data to patients with a shorter history of diabetes and/or higher UA levels at baseline. 
(C) FIGURE 3 Correlations of within-group changes in healthy overweight men (Study-A). A and B, Spearman signed rank test or C, Pearson's correlation was used to assess correlations outcome trials. Interestingly, the association between UA levels and progression of diabetic kidney disease appears to be present only in healthier subjects, that is, those with earlier stages of chronic kidney disease (CKD), 46 and seems to be lost in more advanced CKD. 47, 48 Sixth, the effects of lixisenatide were investigated in the postprandial state and an active comparator was used rather than placebo, which may have led to a more heterogeneous response and thus hampers direct comparison with other reported studies that were performed in the fasting state. Seventh, lixisenatide markedly slows the gastric emptying rate, 23 which could affect purine uptake in the postprandial state.
However, the effects of the mixed breakfast on plasma UA and UE UA were minor at baseline. Finally, although we did not test prolonged treatment effects of exenatide twice-daily, the drug is structurally similar to lixisenatide, and harbours comparable pharmacokinetic and pharmacodynamic properties. 49 As such, we believe it is unlikely that prolonged treatment with this formulation of exenatide would result in differential effects on kidney UA clearance and/or UA levels.
In conclusion, immediate exenatide infusion increases UE UA in healthy overweight men and in T2DM patients by increasing UE UA , possibly mediated by GLP-1RA-induced NHE3 inhibition in the proximal tubule and/or consequent urine alkalization. Prolonged treatment with the long-acting GLP-1RA liraglutide or the short-acting GLP-1RA lixisenatide does not affect UE UA or UA levels in T2DM patients with normal plasma UA levels and relatively low cardiovascular risk.
Our results indicate that it is unlikely that UA is a relevant mediator of the cardiovascular and renal benefits of GLP-1RA.
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